324PAlpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of key adverse events of special interest (AESIs) in SOLAR-1
Rugo, H S, André, F, Yamashita, T, Cerda, H, Toledano, I, Stemmer, S, Cruz Jurado, J, Juric, D, Mayer, I, Ciruelos, E M, Iwata, H, Conte, P F, Campone, M, Wilke, C, Mills, D, Lorenzo, I, Miller, M, LoVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz242.019
Date:
October, 2019
Fichier:
PDF, 100 KB
2019
File converter
Plus de résultats de recherche
More benefits 
